Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Editorial Board | Gut
gut.bmj.com › pages › editorial-board
University of Bern Bern, Switzerland ... Board of Erasmus MC on 1 December 2012 and has chaired the Board since 15 March 2013. He was educated in the Netherlands
Big thunders we know!!!
https://gut.bmj.com/pages/editorial-board/
Our Bio2Brain H2020 Marie-Sklodowska-Curie European Training Network (MSCA-ETN) is offering 13 PhD positions to Early-Stage researchers (ESR).
13 PhD positions in N2B Delivery of Biopharmaceutics for the therapy of CNS diseases
Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB)
Stuttgart, Baden-Württemberg, Germany
Posted about 1 month ago
Expires on March 31, 2021
https://www.nature.com/naturecareers/job/13-phd-positions-in-n2b-delivery-of-biopharmaceutics-for-the-therapy-of-cns-diseases-fraunhofer-institute-for-interfacial-engineering-and-biotechnology-igb-736253
ESR4: Analysis of mAb transport and its dependency on Fc ...
bio2brain.eu › network › esrs
The ESR will be registered for the PhD programme at University of Bern in Switzerland. The overall goal of this subproject is the analysis of the transmucosal pathway through the nasal mucosa and the role of specific mucosal carriers. The specific goals are: Molecular understanding of intranasal transmucosal delivery of antibodies to the CNS;
https://bio2brain.eu/network/esrs/esr4-analysis-of-mab-transport-and-its-dependency-on-fc-interacting-molecules-in-vitro-ex-vivo-and-in-vivo-hbc/
ESR6: Nose to Brain application of wildtype and engineered ...
bio2brain.eu › network › esrs
Job description: The advertised subproject will be carried out by a PhD student (“Early-stage Researcher”: ESR) at the Department of Neurology, University Hospital Inselspital Bern, University of Bern, over a period of 36 months. The recruited researcher will work in the neuroimmunological research group (Center of experimental neurology) led by Prof. Dr. med. Andrew Chan, which brings together basic, clinical and translational research.
https://bio2brain.eu/network/esrs/esr6-nose-to-brain-application-of-wildtype-and-engineered-antibodies-in-the-pathophysiological-context-in-vivo-unibe/
Drug Delivery Compounds | Small Molecule Pharmaceuticals | Merck
www.merckmillipore.com › INTL › en
Drug Delivery Compounds for Enhanced Bioavailability At Merck, we offer high-quality drug delivery compounds that meet your formulation needs and enhance the bioavailability of your API. We are your global partner and offer support in every stage of custom development of Drug Delivery Compounds (DDCs) that fulfill regulatory requirements.
https://www.emdmillipore.com/US/en/products/small-molecule-pharmaceuticals/formulation/bioavailability-enhancement/drug-delivery-compounds/nKKb.qB.SpgAAAFRQuYEZcsQ,nav?ReferrerURL=https%3A%2F%2Fsearch.yahoo.com%2F&bd=1
Nasal Drug Delivery Technology Market to Witness Robust Expansion Throughout Covid 19 by Forecast Period 2021 – 2026 | Merck, Novartis, Johnson & Johnson, Pfizer
February 27, 2021
https://ksusentinel.com/2021/02/27/nasal-drug-delivery-technology-market-to-witness-robust-expansion-throughout-covid-19-by-forecast-period-2021-2026-merck-novartis-johnson-johnson-pfizer/
I don't think Kempers & crew should treat us as stupid
Forest Gump! (stupid is as stupid does) ;)
https://comicbookandbeyond.com/wp-content/uploads/2019/06/Forrest-Gump-saying-1024x542.jpg
Vaccine candidates for COVID-19 - Google Sheets
docs.google.com › spreadsheets › d
VLP recombinant protein + Adjuvant: Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan ... Baylor College of Medicine: COVID-19 ...
https://docs.google.com/spreadsheets/d/1mxyDZHv2suySQYP6LkWWCaB0glLNtxU2uBUTFxRzEhU/edit#gid=0
Christopher Barone's research works | Baylor College of ...
www.researchgate.net › scientific-contributions
Christopher Barone's research while affiliated with Baylor College of Medicine ... or P[2], G3 2/4/6/7-VLPs) or SA11 simian rotavirus in Freund's adjuvants, QS-21 (saponin adjuvant), or al ...
Hmmm GSK using (Virosomes) VLP'S :)
Vaccine quality
Vaccine reference preparations
Vaccine regulation
Publications and media
About
Human Papilloma Virus (HPV) vaccine - 1 dose vial
Container
jpg, 45kb
Package insert
pdf, 1.48Mb
Vaccine Trade Name: Cervarix
Vaccine Type: Bivalent Human Papilloma Virus (Types 16 and 18) Recombinant virus like particle vaccine
Manufacturer: GSK
Country of Manufacture: Belgium
Date of prequalification: 08 July 2009
NRA of Record: Federal Agency for Medicines and Health Products
Product Description
Pharmaceutical form: liquid
Presentation: 1 dose vial
Route of administration: intramuscular
Vaccine Vial Monitor: Type 30
Shelf life: 48 months at 2 - 8 °C
Secondary Packaging:
carton of 1 vial
carton of 10 vials
carton of 100 vials
Cold Chain volume per dose (cm3):
carton of 1 vial : 57.7
carton of 10 vials : 11.5
carton of 100 vials : 9.7
Preservative: None.
Handling of opened multi-dose vials: N/A.
https://www.who.int/immunization_standards/vaccine_quality/PQ_180_HPV_GSK_1_dose/en/
Advancing vaccine development and manufacturing for neglected diseases
Baylor College
Neglected tropical diseases are a group of infectious diseases which commonly disproportionately affect populations in developing countries. According to WHO, these diseases affect one billion people and cost billions of dollars to developing economies every year. Despite of importance for global health, vaccine development for these diseases faces several technical and financial challenges. Development of a high yield and low-cost manufacturing process is key for such vaccine development projects.
We have formed a strategic alliance with Baylor College of Medicine, Houston, Texas to advance vaccine research and development for neglected and emerging infections. The collaboration focuses on bringing vaccines through development to efficiently deliver them to societies in need. Our experts in process development and formulation are working with Texas Children’s CVD scientists at Baylor to optimize the vaccine manufacturing process to increase vaccine stability and yield. Initially, these activities are targeting schistosomiasis, a deadly parasitic disease that affects millions of people a year in tropical and subtropical regions.
Read More Information:
Merck KGaA, Darmstadt, Germany and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
https://www.sigmaaldrich.com/process-solutions/vaccines/collaboration.html
The MilliporeSigma-Baylor teams will improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate,
MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
Company will focus on process development and improvements for manufacturing Baylor’s Covid-19 vaccine candidates
Burlington, Massachusetts, May 27, 2020— MilliporeSigma and Baylor College of Medicine today announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase 1 clinical trials.
https://www.emdmillipore.com/US/en/20200526_192457?ReferrerURL=https%3A%2F%2Fwww.sigmaaldrich.com%2F&bd=1
From Last post: Used Virosomes instead of Alum :) Merck never use Alum again!!
Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples
Correlation between mouse potency and in vitro relative ...
pubmed.ncbi.nlm.nih.gov › 17012876
1 Merck Research Laboratories Department of Bioprocess & Bioanalytical Research, West Point, Pennsylvania, USA. Mary_Retzlaff@merck.com ... Virosomes Substances Human ...
https://pubmed.ncbi.nlm.nih.gov/17012876/
Virus-like particles (VLPs) are an effective means of establishing both prophylactic and therapeutic immunity against their source virus or heterologous antigens. The particulate nature and repetitive structure of VLPs makes them ideal for stimulating potent immune responses. Epitopes delivered by VLPs can be presented on MHC-II for stimulation of a humoral immune response, or cross-presented onto MHC-I leading to cell-mediated immunity. VLPs as particulate subunit vaccine carriers are showing promise in preclinical and clinical trials for the treatment of many conditions including cancer, autoimmunity, allergies and addiction. Supporting the delivery of almost any form of antigenic material, VLPs are ideal candidate vectors for development of future vaccines.
https://www.future-science.com/doi/10.4155/tde.14.74
Pevion Biotech Ltd. announced the appointment of Didier Hoch as Chairman of its Board of Directors. Until recently, Dr Hoch was President of Sanofi-Pasteur MSD, where he played a pivotal role in launching innovative vaccines, such as Gardasil®, in Europe.
11-Feb-2011 - Pevion Biotech Ltd.
https://www.bionity.com/en/news/130772/pevion-appoints-didier-hoch-as-chairman-of-the-board.html
The accidental CDMO
36:44 minutes
In this episode of Molecule to Market, your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Richard Johnson, Founding Director of Upperton Pharma Solutions.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:
Greater collaboration and alliance between smaller, specialist early phase contract service providers as a way to compete against the global one-stop-shops.
Increased demand for nasal and pulmonary delivery as a result oft the pandemic and why Richard was not surprised to see a Covid-19 vaccine developed so quickly.
The contrast of founding a steady 20-year growth business and the another that exited in just five years.
The increasing demand and application for spray drying technology to solve modern pharmaceutical development challenges.
https://www.moleculetomarketpod.com/episodes/the-accidental-cdmo/
Stiftung Europainstitut Basel (Foundation of the Institute)
Stiftung Europainstitut Basel (Foundation of the Institute) has been supporting the Institute since its early years. The foundation board consists of personalities from the cantonal governments and administrations as well as from politics and the business sector. The board discusses questions concerning its mission (namely the use of the foundation funds, maintenance of the building, recommendations for strategic decisions). Furthermore, the board supports the Institute for European Global Studies with its activities of networking in the city and region of Basel.
Dr. Thomas Staehelin, President (Advocate)
https://europa.unibas.ch/en/community/stiftung-europainstitut-basel/
purpose:
The purpose of the company is to invest in companies at home and abroad, to manage assets and to make investments. It can acquire, manage and sell properties.
Eardley Holding AG, in Basel, CHE-100.646.361, Aktiengesellschaft (SHAB No. 218 of 11.11.2019, publ. 1004756501). Peoples registration new or modified: Staehelin, Dr. Thomas, from Basel, in Vitznau, Chairman of the Board of Directors, with individual signature [previously: member of the Board of Directors, with individual signature]; Gähwiler, Felix, von Kirchberg (SG), in Zumikon, member of the board of directors, with joint signature by two [previously: without a registered function, with joint signature by two]
Section: Entries in the commercial register
Sub-heading: Mutation
Publication date: SHAB 03/24/2021
Message number: HR02-1005132158
Publishing body
Federal Office of Justice (FOJ), Federal Office for the Commercial Register, Bundesrain 20, 3003 Bern
Mutation Eardley Holding AG, Basel
Eardley Holding AG
(Eardley Holding SA) (Eardley Holding Ltd)
c / o Dr. Thomas Staehelin
St.Jakobs-Str. 7th
4052 Basel
Eardley Holding AG, in Basel, CHE-100.646.361, Aktiengesellschaft (SHAB No. 218 of
11.11.2019, publ. 1004756501). Peoples registration new or changed: Staehelin,
Dr. Thomas, from Basel, in Vitznau, Chairman of the Board of Directors, with individual signature
[previously: Member of the Board of Directors, with individual signature]; Gähwiler, Felix, from
Kirchberg (SG), in Zumikon, member of the board of directors, with collective signature
two [previously: without a registered function, with a collective signature of two].
Daily register no. 1720 from March 19, 2021
Previous publication in SHAB: No. 218, date: 11/11/2019
Contact point: Commercial Register Office of the Canton of Basel-Stadt
https://www.shab.ch/shabforms/servlet/Search?EID=7&DOCID=1005132158
https://www.zefix.ch/en/search/entity/list/firm/48427
Nicolas Cottier
Corporate Lawyer, CAS Arbitrator, Independent Director
Lausanne, Vaud, Switzerland
About
Corporate lawyer focusing on corporate restructuring, M&A and contract negotiations, advising clients in Switzerland and abroad in French, English and German. Strong knowledge of tax and accounting matters thanks to a 13 years experience at KPMG and a strong network of tax and accounting specialists. Sports law and Corporate Governance as additional areas of specialisation. Member of the board of various companies.
Specialties:Corporate restructuring, M&A, contract drafting and contract negotiation
Sector skills: energy, transportation and sport federations
https://www.linkedin.com/in/nicolas-cottier-6972276/?originalSubdomain=ch
.. Head of the Department of Economic Promotion and Trade (SPECo) of the Canton of Vaud. Nicolas Cottier, administrator, founder ... Anergis SA ARIAD Pharmaceuticals BDO SA Biomapas SA Biopôle Dental Clinic SA BOAS HOTEL AQUATIS CILE - Imaging Center of ... Mymetics SA Nestlé Health Sciences Novassay Novigenix Outsourcing-Development Parenthesis NOW * - Agence de communication ... Department of Economic Promotion and Trade (SPECo) Greater Geneva Berne area (GGBA) Innovaud (Official site) Swiss ...
https://lookformedical.com/fr/wikipedia/dental-health-services
Novel birch pollen specific immunotherapy formulation based ...
ctajournal.biomedcentral.com › articles › 10
Jun 01, 2013 · von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, Spertini F: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol. 2000, 30: 1638-1645. 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R.
Author: Céline Pellaton, Yannick Perrin, Caroline Boudousquié, Nathalie Barbier, Jacqueline Wassenberg, Giam...
Cited by: 67
https://ctajournal.biomedcentral.com/articles/10.1186/2045-7022-3-17
Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis
Christophe von Garnier Mireille Astori Alexander Kettner Nathalie Dufour Christoph Heusser Giampietro Corradin François Spertini
https://onlinelibrary.wiley.com/doi/10.1002/1521-4141%28200006%2930%3A6%3C1638%3A%3AAID-IMMU1638%3E3.0.CO%3B2-R
https://covid19crc.org/about-us/coalition-members/
https://covid19crc.org/
Botnar Foundation | Tanzania – Hassan Mshinda*
Baylor College of Medicine | USA – Maria Elena Bottazzi*, Shubhada Hooli, Peter Hotez*
Bill & Melinda Gates Foundation | USA – Trevor Mundel*
Drugs for Neglected Diseases initiative (DNDi) | Switzerland – Michelle Childs, Pascale Boulet, Marie-Paule Kieny*, Bernard Pécoul*, Nathalie Strub-Wourgaft*
Institute of Social and Preventive Medicine (ISPM), University of Bern | Switzerland – Oscar Franco
Institute of Global Health, University of Geneva | Switzerland – Antoine Flahault*
Medicines for Malaria Venture | Switzerland – David Reddy*
PATH Center for Vaccine Innovation and Access | USA – Jorge Flores, Jennifer O’Reilly
Swiss TPH | Switzerland – Juerg Utzinger*
and MORE/ Probably missed some!!
Vaccines and Therapeutics
The Vaccines and Therapeutics Task Force published a Comment in Lancet on Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics (28 January 2021).
Dr. Maria Elena Bottazzi (Co-chair) Associate Dean, National School of Tropical Medicine (USA)
Dr. Peter Hotez (Co-chair) Dean of the National School of Tropical Medicine, Baylor College of Medicine (USA)
Dr. Sarah Gilbert Professor of Vaccinology, Nuffield Department of Clinical Medicine, University of Oxford (UK)
Dr. David C. Kaslow Chief Scientific Officer, PATH Essential Medicines & Head, PATH Center for Vaccine Innovation and Access (USA)
https://covid19commission.org/vaccines-therapeutics
David C. Kaslow, MD,
http://scienceoferadication.org/faculty-member/kaslow-david/
David C. Kaslow, M.D.,joined us as Chief Scientific Officer in October 2001. Dr. Kaslow has more than 15 years of vaccine research experience. Dr. Kaslow joined Merck in February 1999 as Senior Director, Vaccine Research, and was employed by Merck, most recently as Head of the Department of Vaccine Research and Technology, until he joined Vical. From 1986 to 1999, he held various senior research positions at the NIH, including Head of the Recombinant Protein Development Unit and the Malaria Vaccine
Development Unit at the Laboratory of Parasitic Diseases. Dr. Kaslow has been awarded numerous professional honors, including the U.S. Public Health Service Outstanding Service Medal. He has published more than 120 scientific papers, and authored more than 20 review articles and book chapters. He holds or co-holds 13 patents. Dr. Kaslow received his M.D. from the School of Medicine at the University of California, San Francisco, in 1983 and his bachelor’s degree from the University of California, Davis, in 1979.
Knows Texas Pete!! :)
https://www.spoke.com/people/david-kaslow-3e1429c09e597c10001362f3
Same Gal?
Susan Linna
VP Project Management at Emergent Biosolutions
Germantown, Maryland, United States
Emergent Biosolutions
VP Project Management
Company Name Emergent Biosolutions
Education
Western Michigan University
Western Michigan University
Dates attended or expected graduation1979 – 1987
David C. Kaslow, M.D.
Chief Scientific Officer, PATH and Head, PATH's Center for Vaccine Innovation and Access (CVIA)
PATH
Total Duration9 yrs 1 mo
Title Chief Scientific Officer
Full-time
Dates Employed Oct 2020 – Present
Employment Duration6 mos
Location Seattle, Washington, United States
Title Head, PATH's Center for Vaccine Innovation and Access (CVIA)
Full-time
Dates Employed Mar 2016 – Present
Employment Duration5 yrs 1 mo
Location Seattle, Washington, United States
Title Vice President, Essential Medicines
Dates Employed Feb 2017 – Oct 2020
Employment Duration3 yrs 9 mos
Location Seattle, WA USA
Title Vice President, Product Development
Dates Employed Oct 2013 – Jan 2017
Employment Duration3 yrs 4 mos
Location Seattle, WA USA
Title Director, Malaria Vaccine Initiative
Dates Employed Mar 2012 – Sep 2013
Employment Duration1 yr 7 mos
Location Washington, DC USA
Merck
Total Duration5 yrs 8 mos
Title Vice President and Head, Vaccines Integration and Pipeline Management, Merck Research Laboratories
Dates Employed Nov 2009 – Mar 2012
Employment Duration2 yrs 5 mos
Location Upper Gwynedd, PA USA
Title Vice President and Franchise Integrator, Vaccines & Infectious Diseases, Merck Research Laboratories
Dates Employed Aug 2006 – Oct 2009
Employment Duration3 yrs 3 mos
Location Upper Gwynedd, PA USA
Section Head, Malaria Vaccine Section & Malaria Vaccine Development Unit
Company Name National Institute of Allergy and Infectious Diseases (NIAID) Full-time
Dates Employed1986 – 1999
Employment Duration13 yrs
Location Bethesda, MD USA
Commander, USPHS
Merck
Senior Director, Merck Research Laboratories
Company Name Merck
Dates Employed Feb 1999 – Oct 2001
Employment Duration2 yrs 9 mos
LocationWest Point, PA USA
Lanying Du, PhD
Title
Head, Laboratory of Viral Immunology
Member, Lindsley F. Kimball Research Institute
Research on coronaviruses
MERS-CoV vaccines and pathogenic mechanisms. We have identified MERS-CoV spike protein receptor-binding domain (RBD) as an important vaccine target, and demonstrated that MERS-CoV RBD contains a critical neutralizing domain capable of inducing cross-neutralizing antibodies against infection of divergent MERS-CoV strains. Current research focus is to design and develop safe, efficacious, and novel MERS vaccines with low-cost, manufacturing capacity, broad-spectrum efficacy, and enhanced potency, identify their protective mechanisms, and study pathogenic mechanisms of MERS-CoV.
Other coronavirus vaccines and pathogenic mechanisms. We have shown that SARS-CoV-2 and SARS-CoV spike proteins and RBDs are important vaccine targets. We are working on the development of novel spike protein and/or RBD-based vaccines against SARS-CoV-2 (COVID-19), SARS-CoV and other coronaviruses with pandemic potential, study of their protective mechanisms, as well as identification of pathogenic mechanisms of these coronaviruses.
Therapeutic antibodies against pathogenic coronaviruses. We have demonstrated that coronavirus spike proteins and RBDs are important therapeutic targets. Current research focus is to design and develop spike protein and/or RBD-targeting novel therapeutic antibodies against emerging coronaviruses with pandemic potential.
https://nybloodcenter.org/lindsley-f-kimball-research-institute/investigators/lanying-du/
https://www.hhs.gov/sites/default/files/nvac_june2020_panel1.pdf?fbclid=IwAR30vPhF5s4cpRzSdZAny7B_IeEhtDnisvK_H31_KxyFCCIFAFj1Q3QFbjs
00:02
Basel is a wonderful place and we have been doing quite well over the past few years,
00:07
structurally, the economy is doing well. Last but not least, the pharmaceutical industry, which has had a strong impact, has also created many jobs with suppliers, with SMEs.
00:18
And it is precisely this prosperity that we must not jeopardize now; the Corona crisis in particular has shown that prosperity is anything but self-evident.
00:29
If I am re-elected to the government council on October 25th, I would like to help in the new legislature
00:37
together with Conradin Cramer, Lukas Engelberger, Stefanie Eymann and all others who are elected,
00:44
that we get out of this corona crisis step by step,
00:47
that we defend ourselves against extreme demands from the left and right.
00:50
Now is not the time for experiments, but with a lot of pragmatism, with good leadership, to get out of this corona crisis step by step.
More about this source textSource text required for additional translation information
Send feedback
Side panels
Windfall sale of Mymx? That's alot of Mo-la ;)
Mymetics Corp. - Relationship Science
relationshipscience.com › organization › mymetics
Ernest M. Stern. Partner at Akerman LLP. ... Peterson Sullivan LLP. Advised onMymetics Corp. purchases Gruppo San Rocco SpA . Key Stats and Financials As of 2019.
BDO expands in Pacific Northwest with Peterson Sullivan
https://www.accountingtoday.com/news/bdo-usa-expands-in-northwest-with-peterson-sullivan-acquisition
Tollys S.A.S.. (5/26/20). "Press Release: Tollys Closes Series A Financing of €2.3 Million". Lyon.
Three new executives are joining Tollys president Jacques-François Martin on the board of directors. Independent members Dr. Dino Dina, a former CEO of Dynavax corporation and of Chiron Vaccines and Mr Philippe Goupit, a biotech and pharmaceutical industry veteran, are joined by Ms Céline Baque Saint-Olive, CEO of Noraker and a representative of Tollys private investors.
“Tollys is excited to have attracted the support of its series A investors and to have three new highly experienced industry executives on our board,” said Jacques-François Martin, president of Tollys. “This is a strong endorsement of our company, our vision and our capabilities in delivering on TL-532, a new cancer immunotherapy, which has demonstrated much promise.”
https://www.life-sciences-europe.com/news/tollys-closes-series-financing-andrew-lloyd-associates-ala-2001-116843.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155972253
Where's VC ?
World Health Organization WHO
Consultation on potential Ebola therapies and vaccines
4-5 September 2014
Geneva, Starling Hotel
List of participants:
85. Dr Jacques-François Martin, Fab Entech, Lyon, France
https://www.who.int/mediacentre/events/meetings/2014/lop-ebola-consultation.pdf
Innosuisse and AlveoliX
https://www.alveolix.com/wp-content/uploads/2021/02/Article.pdf